CA2153781A1 - Methode pour traiter la douleur myofaciale - Google Patents

Methode pour traiter la douleur myofaciale

Info

Publication number
CA2153781A1
CA2153781A1 CA002153781A CA2153781A CA2153781A1 CA 2153781 A1 CA2153781 A1 CA 2153781A1 CA 002153781 A CA002153781 A CA 002153781A CA 2153781 A CA2153781 A CA 2153781A CA 2153781 A1 CA2153781 A1 CA 2153781A1
Authority
CA
Canada
Prior art keywords
pain
muscle
medicament
syndrome
toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002153781A
Other languages
English (en)
Inventor
Gary E. Borodic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Associated Synapse Biologics
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2153781A1 publication Critical patent/CA2153781A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002153781A 1993-01-15 1994-01-13 Methode pour traiter la douleur myofaciale Abandoned CA2153781A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US504093A 1993-01-15 1993-01-15
US08/005,040 1993-01-15

Publications (1)

Publication Number Publication Date
CA2153781A1 true CA2153781A1 (fr) 1994-07-21

Family

ID=21713832

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002153781A Abandoned CA2153781A1 (fr) 1993-01-15 1994-01-13 Methode pour traiter la douleur myofaciale

Country Status (5)

Country Link
EP (1) EP0679090A1 (fr)
JP (1) JP4381477B2 (fr)
AU (1) AU6030494A (fr)
CA (1) CA2153781A1 (fr)
WO (1) WO1994015629A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US8557256B2 (en) 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
ES2347384T3 (es) * 1993-12-28 2010-10-28 Allergan, Inc. Componente neurotoxico de una toxina botulinica para tratar de discinesia tardia.
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
DK1086702T3 (da) * 1994-05-09 2005-05-23 William J Binder Præsynaptiske neurotoksiner til behandling af migrænehovedpine
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6565870B1 (en) 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US7691983B2 (en) 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US20150258183A1 (en) 2006-06-07 2015-09-17 Botulinum Toxin Research Associates, Inc. Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053005A (en) * 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals

Also Published As

Publication number Publication date
AU6030494A (en) 1994-08-15
JPH08508241A (ja) 1996-09-03
WO1994015629A1 (fr) 1994-07-21
EP0679090A1 (fr) 1995-11-02
JP4381477B2 (ja) 2009-12-09

Similar Documents

Publication Publication Date Title
CA2153781A1 (fr) Methode pour traiter la douleur myofaciale
US6632433B2 (en) Method for treating cervical dystonia with botulinum toxin type B
EP1757325B1 (fr) Utilisation de la toxine botulinique pour traiter les douleurs myofasciales
Meythaler et al. Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report
US8187612B2 (en) Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
EP1487481A2 (fr) Methodes de traitement de syndromes nerveux compressifs
WO2003063898A2 (fr) Procede de traitement de la douleur
Ward et al. The management of pain in spasticity
Glenn et al. Chemical denervation for the treatment of hypertonia and related motor disorders: phenol and botulinum toxin
AU727737B2 (en) Method for treating dysphagia
Patil et al. Application of Botulinum Toxin in Myofascial Pain Dysfunction Syndrome
CA2300766C (fr) Methode pour traiter une secretion cholinergique influencee
CA2589987C (fr) Methode pour traiter une secretion cholinergique influencee
AU2005200248B2 (en) Method for treating dystonia with botulinum toxin type B
De Andrés New advances in botulinum toxin therapy for pain
Guerri A SYSTEMATIC REVIEW OF OBSERVATIONAL STUDIES OF PATIENTS WITH OCULAR HYPERTENSION OR GLAUCOMA RECEIVING LONG TERM TOPICAL EYE THERAPIES
Stevenson Focal treatments, including botulinum toxin
AU1636500A (en) Method for treating a mucus secretion
AU2003202374A1 (en) Method of treating pain with botulinum toxin
AU1636700A (en) Method for treating dystonia with botulinum toxin type B

Legal Events

Date Code Title Description
FZDE Dead